ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

8 Things You Need to Know about New SGLT2 Inhibitor Study


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

scientist conducting SGLT2 study in lab

A recent study showed some benefits to taking SGLT2 inhibitors to treat Type 2 diabetes.

The study compared certain SGLT2 inhibitors with other glucose-lowering drugs (oGLDs).

Results showed patients taking SGLT2 inhibitors to treat Type 2 diabetes were less likely to experience heart attack and stroke than patients using oGLDs.

The study also suggested SGLT2 inhibitors might offer Type 2 diabetes patients certain heart and cardiovascular benefits over oGLDs.

But the study results don’t tell consumers the whole story.

Here’s eight things consumers need to know about the latest SGLT2 inhibitor study:

  1. AstraZeneca funded the study. The multinational pharmaceutical company manufactures SGLT2 inhibitors.
  2. The study’s author stressed the need for longer-term follow-up to see whether the positive effects seen in the study would last.
  3. Dapagliflozin (Farxiga) was among the SGLT2 inhibitors studied. AstraZeneca manufactures Farxiga.
  4. Researchers also studied empagliflozin (Jardiance), ipragliflozin (Suglat), canagliflozin (Invokana), tofogliflozin and luseogliflozin. They did not specify which oGLDs they studied.
  5. The study excluded safety data. The medical community uses patient safety data to prevent side effects and to confirm the overall safety of a drug or treatment.
  6. Previous studies have linked SGLT2 inhibitors to serious and even life-threatening side effects. These include an increased risk of amputation, and blood and kidney infections.
  7. Researchers gathered data for the study from patient medical records and claims databases. They did not have the data independently verified against the source documents.
  8. The study was observational. So, its authors noted the possibility of other factors that could have influenced the outcome.

Dr. Mikhail Kosiborod presented the study results this month at the 67th American College of Cardiology Scientific Sessions in Orlando.  The Journal of the American College of Cardiology simultaneously published the study.

Kristin Compton
Written By Kristin Compton Writer

Kristin Compton's background is in legal studies. She worked as a paralegal before joining Drugwatch as a writer and researcher. She was also a member of the National Association of Legal Assistants. A mother and longtime patient, she has firsthand experience of the harmful effects prescription drugs can have on women and their children. Some of her qualifications include:

  • Bachelor of Arts in Legal Studies | Pre-Law from University of West Florida
  • Past employment with The Health Law Firm and Kerrigan, Estess, Rankin, McLeod & Thompson LLC
  • Personal experience battling severe food allergies, asthma and high-risk pregnancies
Edited By
Emily Miller
Emily Miller Managing Editor

4 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Hoffman, M. (2018, March 11). SGLT-2 Inhibitors Linked to Lowered Risk of Mortality, MI, Stroke, and Hospitalization for Heart Failure. MD Magazine. Retrieved from
  2. Kosiborod, M. et al. (2018, March). Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-Real 2 Study. Journal of the American College of Cardiology. Retrieved from
  3. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). (2017, February). Diabetes, Heart Disease, and Stroke. National Institutes of Health. Retrieved from
  4. U.S. Food and Drug Administration. (2017, May 16). Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617